Literature DB >> 7449787

Successful long-term phenobarbital therapy of hyperbilirubinemia in congenital hemolytic anemia due to glucose phosphate isomerase deficiency.

W Schröter.   

Abstract

Long-term phenobarbital treatment (2 mg/kg body weight/day) permanently reduced hyperbilirubinemia in a patient with congenital non-spherocytic hemolytic anemia due to erythrocyte glucose phosphate isomerase deficiency. Phenobarbital treatment is recommended in patients with congenital hemolytic anemia in whom hyperbilirubinemia is not improved by splenectomy or in whom splenectomy is not indicated. Early phenobarbital treatment may prevent the development of cholelithiasis in patients with chronic hemolysis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7449787     DOI: 10.1007/bf00445891

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  22 in total

1.  Cholelithiasis in sickle cell anemia.

Authors:  A A MINTZ; G CHURCH; E D ADAMS
Journal:  J Pediatr       Date:  1955-08       Impact factor: 4.406

2.  Effect of phenobarbital on hepatic transport and excretion of 131 I-rose bengal in children with cholestasis.

Authors:  M M Thaler
Journal:  Pediatr Res       Date:  1972-02       Impact factor: 3.756

3.  Reduction in concentration of total serum-bilirubin in offspring of women treated with phenobarbitone during pregnancy.

Authors:  H M Maurer; J A Wolff; M Finster; P J Poppers; E Pantuck; R Kuntzman; A H Conney
Journal:  Lancet       Date:  1968-07-20       Impact factor: 79.321

4.  Decrease of total serum-bilirubin concentration in newborn infants after phenobarbitone treatment.

Authors:  D Trolle
Journal:  Lancet       Date:  1968-09-28       Impact factor: 79.321

5.  The effects of phenobarbital on bile salts and bilirubin in patients with intrahepatic and extrahepatic cholestasis.

Authors:  A Stiehl; M M Thaler; W H Admirand
Journal:  N Engl J Med       Date:  1972-04-20       Impact factor: 91.245

6.  Phenobarbitone enhancement of bromsulphalein clearance in neonatal hyperbilirubinemia.

Authors:  C Y Yeung; V Y Yu
Journal:  Pediatrics       Date:  1971-10       Impact factor: 7.124

7.  Reduction in serum bilirubin by phenobarbital in adult unconjugated hyperhilirubinaemia. Is enzyme induction responsible?

Authors:  M J Whelton; L P Krustev; B H Billing
Journal:  Am J Med       Date:  1968-07       Impact factor: 4.965

8.  Phenobarbital effects in cholestatic liver diseases.

Authors:  J R Bloomer; J L Boyer
Journal:  Ann Intern Med       Date:  1975-03       Impact factor: 25.391

9.  Efficacy and safety of long-term phenobarbital therapy of familial cholestasis.

Authors:  C N Ghent; J R Bloomer; Y E Hsia
Journal:  J Pediatr       Date:  1978-07       Impact factor: 4.406

10.  Effect of sodium phenobarbital on bilirubin metabolism in an infant with congenital, nonhemolytic, unconjugated hyperbilirubinemia, and kernicterus.

Authors:  J F Crigler; N I Gold
Journal:  J Clin Invest       Date:  1969-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.